Please assess the completion status of the following clinical trial:

Trial Title: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 years or older on the day of signing the Informed Consent Form (ICF).~* Histologically confirmed indolent/aggressive DLBCL, FL, MZL, or MCL.~* Participants with DLBCL, MZL or MCL must have received at least 1 prior line of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.~* Participants with FL must have received at least 2 prior lines of systemic therapy with documented progression or documented failure to achieve CR or PR after the most recent systemic treatment regimen.~* Ineligible for stem cell transplant.~* Participants with DLBCL must have failed or refused stem cell transplantation or failed first-line salvage therapy if ineligible for transplantation.~* Must be willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue.~* Life expectancy of \> 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 (see Appendix D).~* Willingness to avoid pregnancy or fathering a child.~* Ability to comprehend and willingness to sign an ICF~Exclusion Criteria:~* Evidence of transformed non-Hodgkin lymphoma histologies (with the exception of FL).~* Histologically confirmed rare non-Hodgkin B-cell subtypes.~* History of or central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.~* Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor.~* For participants to be treated with bendamustine (Treatment B), prior treatment with bendamustine (within 12 months of the start of study treatment). Participants with prior bendamustine treatment (\> 12 months before the start of study treatment) are eligible if they meet the following criteria:~  * Did not discontinue because of tolerability concerns.~ * Achieved either partial response (PR) or complete response (CR) to the bendamustine regimen of at least 12 months in duration before relapse/progression.~ * Experienced progression following a regimen containing an alkylating agent.~* For participants to be treated with ibrutinib (Treatment C), prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor.~* Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.~* Active graft-versus-host disease following allogeneic transplant.~* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): Parsaclisib + Rituximab
- Treatment B (Type: EXPERIMENTAL): Parsaclisib + Bendamustine + Rituximab
- Treatment C (Type: EXPERIMENTAL): Parsaclisib + Ibrutinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete